The leading CEO forum for pharmaceutical producers, distributors and retailers in Russia

12 - 13 May 2021

Corinthia Saint-Petersburg Hotel

Speaker confirmations in 2020

Elena is recognized expert and leader of the Russian pharmaceutical industry, has 25 years of experience in leading international pharmaceutical companies, one of 25 women CEO of Russia according to RBC. 
 
2019 till present – President of the company Takeda Pharmaceuticals Russia 
2014-2019 General Manager, Abbott Russia 
2011-2014 General Manager, Meda Pharmaceuticals 
1995-2011 kept different positions in sales and marketing in such pharmaceutical companies as Pliva (Croatia), Novartis Pharma (Switzerland), Sanofi (France). 
1990-1993 graduated from the Oncology Institute of Russian Academy of Sciences., PhD. 
1987 graduated from the Moscow Medical Academy n.a. Sechenov, Department of General Medicine.

Mr. Gunaydin joined Amgen Russia in 2019. He has a wide international experience in pharma industry with varying responsibilities in countries like Turkey, Middle East & United States and in different roles in Finance, Strategy and Sales & Marketing areas. Mr. Gunaydin holds an MA in Economics from the Bosphorus University, Istanbul.

Irina joined Eli Lilly team in 2001 as a Brand Manager, and has since advanced to General Manager of Eli Lilly Russia/CIS. For the past 20 years she had worked in key marketing and sales roles, was the head of HR function, and led the efforts to implement Six Sigma principles to refine the business processes at Lilly. Irina served as Senior Director for Ethics and Compliance, International Business Unit at the company’s headquarters in the US. Irina is currently focusing on strengthening the company’s position in oncology, diabetes and immunology in Russia and CIS as well as accelerating the path to market for Lilly’s innovative molecules. Irina obtained her MBA degree at the Weatherhead School of Management, Case Western Reserve University in Ohio, USA.

Inna Bakumenko joined Abbott as the General Manager in November 2019. The key priorities in this role are strategic portfolio development, digital transformation, and scaling up of management expertise to the country cluster. Inna has over 20 years of professional experience in the pharmaceutical industry in Russia and CIS. Prior to joining Abbott, Inna was in charge of Pfizer GEP in Russia and General Manager of Pfizer Upjoin in Russia. Early in her career, Inna worked as a medical representative of Janssen-Cilag, Johnson & Johnson’s division. Then she took various roles in sales and marketing and was in charge of business units of Servier, Allergan and Pfizer in Ukraine. From 2015 Inna was the General Manager of Pfizer in Ukraine and a regional head of GEP business in Ukraine, Caucasus and Central Asia. Inna received higher medical degree at Kharkov National Medical University and master's in marketing and management at the National Economical University by European program TACIS, and Harvard Business School.

Dr. Stephan Eder is Executive Vice President of STADA in the Russia and CIS region, and a member of the Global STADA Executive Committee. In this role, he oversees all operations in STADA Russia as well as in the CIS countries. Russia is with more than 3000 employees the second largest business within the global STADA Group.

He joined STADA from Sandoz, where he most recently served as CEO Hexal and Country Head Sandoz Germany from mid-2017 onwards. With a clear vision, he led the German Sandoz team and business through a strategic transformation to drive increased customer focus, resulting in strong sales and profit growth as well as an expansion of market leadership in Germany.

Having started his career at McKinsey, Austrian national Stephan Eder was co-founder and CFO of the startup medicine-discovery company 55pharma before joining Sandoz’ parent group, Novartis, in 2007. After working in corporate strategy roles at Novartis, he subsequently led Sandoz’ portfolio management, business development and licensing function in Central and Eastern Europe before he was responsible for the Russian OTC operation from mid-2010 until end 2013. During this period under his leadership, the business almost doubled in size and strongly outgrew the Russian OTC market. Subsequently until mid-2017, Stephan Eder headed Sandoz’ operations in the UK and Ireland as General Manager, successfully growing the business and driving sustainable results in a highly volatile market.

Elena owns more than15 year experience in pharma with a proven track record in driving marketing, sales, and corporate strategy development.

Elena launched her professional career in Marketing in Boehringer Ingelheim, one of the leading German pharma companies, having worked there for 10 years. Moving forward, Elena had various executive positions in Russian, American and Indian pharma companies, gaining valuable international experience and building a wide network of contacts with partners.

Elena graduated from Baikal International Business School of Irkutsk State University (Siberian-American Department of Management). Also she has a degree of Global Executive MBA of Vienna University of Economics and Business and of University of Minnesota.

Since 2018, he has been the Executive Director of NANOLEK; in March 2020, he joined the Management Board of Nanolek LLC. During his work, he managed to increase the number of sales by several times, carried out global structural changes, bringing the company first profit and ensuring the export of medicines to the CIS countries.

Prior to joining NANOLEK, he had worked for companies such as Elly Lilly Vostok S.A., Pharmstandard, NPO PetrovaxPharm.

Maxim Stetsyuk graduated from the State Academy of Management, in2006–2008completed training in the University of Antwerp Management School (UAMS), has international certificates business schools. 

«If we talk about developing a common strategy within the framework of healthcare, we must remember that a profitable investment is a contribution to disease prevention».

«Our company has a GMP quality certificate and passes audits of foreign partners at least 1–2 times a month, and such a check can be passed only in one case: if you do not have a single violation throughout the entire production chain. I invite everyone to make sure of this at the NANOLEK plant in the Kirov region».

Adlane graduated in Marketing and Management from Lyon Business School and holds a Master’s Degree in International Trade from Lyon University.

Adlane Soudani joined Ipsen in France in 2005. He developed a specific expertise in the export business in several regions of the globe until he was promoted to Export Director for Latin America.

Building on his success in this role, in 2013 he was appointed General Manager, Ipsen in Algeria. In this position, he has been instrumental in building a strong team and leading it to reach record market shares for both the Specialty Care and Consumer Healthcare businesses.

Demonstrating a lot of resilience in a challenging market like Russia, Adlane successfully led the creation of a Joint-Venture in the country which has paved the way for building the first oncology factory in the Algeria. 

In October 2018 Adlane was appointed a General Manager of Ipsen in Russia & CIS.

Since then the company has started its fantastic transformation journey. Within a relatively short period of time Adlane managed to develop new capabilities within the company to be more focused on innovation and breakthrough solutions in oncology and rare diseases.  Thanks to the recently launched innovative breakthrough solution for kidney cancer treatment and other product yet to come for patients` unmet needs, Ipsen is transforming into one of the key players in oncology and orphan disease markets in Russia.

Adlane`s key focus in patient centricity and development of business in a compliant manner helped to bring innovation for the development of the company which can contribute to the development of the healthcare industry in Russia.

Ivan Poljak is General Manager of Abbott’s Veropharm, one of Russia’s leading healthcare manufacturers. Before heading Abbott’s Veropharm business, Ivan held the position of Senior Director Commercial Development, Strategy and Sales in Abbott’s medicines business. 
Ivan’s experience combines international expertise with a strong understanding of country specifics, and an insight-driven approach to business. He has more than 20 years of experience leading successful teams at international healthcare companies, working in the United States, Asia and Europe. Ivan has strong experience in new product launches, life cycle management, sales force excellence and market research. 
Ivan has a Bachelor of Science degree in Business Administration from S.R. Univesity in the U.S. and an MBA from Thunderbird Graduate School of International Management in the U.S. He also completed executive education programs at INSEAD in France and Saïd Business School at the University of Oxford in Great Britain. Ivan was born in Belgrad, Serbia. He is fluent in five languages, including Russian and English.

The head of "ERKAFARM" group of companies since June 2012. Earlier, from 2009 to 2012, she has successfully performed as the deputy of General Director for Commerce. Under the leadership of Anastasia, the company has become one of the leaders in the pharmaceutical industry and from 2014 has been in the TOP-3 pharmaceutical chains in Russia. Before joining ERKAFARM, Anastasia worked for the "Protek" group of companies being the head of marketing and advertising department of the "Rigla" pharmacy chain.

The CEO of the ERKAFARM group of companies is included in the ranking of the TOP-100 economic leaders in Russia. Anastasis is among the leaders in the TOP-25 most influential female CEO ranking, which is annually published by RBC magazine, she is the manager who has never left this list since it was established. She is ranked 10th on the Kommersant newspaper's TOP-1,000 Russian Managers list in the pharmaceutical category. She was included in the TOP-1,000 most effective executives list compiled by the business publication Delovoy Peterburg.

Anastasia graduated from the State University - Higher School of Economics and also finished educational program EMBA (Executive Master of Business Admini- stration) program at Saïd Business School, University of Oxford (Oxford University Business School).

Graduated from the Geography Department of Kazan Federal University. Received an MBA at the Management School of Lancaster University (UK). Has over 20 years of experience in senior managerial positions in the pharmaceutical industry.

In 2011 won the “Manager of the Year” as per Platinum Ounce award, a prominent professional award in the Russian pharmaceutical field. In 2015, became the Head of the Eurasia business unit — encompassing Russia, the CIS states, Georgia and the Ukraine — in a pharmaceutical company Bosnalijek (Bosnia and Herzegovina), one of the largest pharmaceutical manufacturers in the Balkan States and Eastern Europe. Recently, the business unit led by Valentina has increased its influence by entering the markets of Kazakhstan, Belarus and Azerbaijan.

In 2017, Bosnalijek, with its production sites in Sarajevo, became one of the first companies that had its application approved by the Russian Ministry of Industry and Trade and received a GMP certificate. The Russian market is vital to Bosnalijek’s future; it is the second year in a row that Bosnalijek sales continue to grow at a double-digit rate, which is significantly faster than the market. Bosnalijek best sellers are LYSOBACT and ENTEROFURYL, ranking among Top 3 in their categories.

Elena Nevolina, Ph. D. in Pharmaceutical Science, is Executive Director of the National Pharmaceutical Chamber in Russia, has an extensive experience in pharmaceutical industry since 1985

For more than 10 years, she was Head of the Control and Audit department of the Main Pharmacy Administration of Soviet Ministry of Health, later taking up executive positions in pharmaceutical associations. Now Elena Nevolina is Executive Director of association “Pharmacy Guild” (since 2006) and Executive Director of association “National Pharmaceutical Chamber” (since 2014) being an active contributor to the development of the Russian pharmaceutical industry and main self-care advocate in Russia


Elena Nevolina is an expert of the Russian Government Expert Council, a member of self-regulation Committee of the Chamber of Industry and Commerce, Executive Secretary (in pharmacy) of the Council for Professional Qualifications, an expert on regulatory impact assessment of Ministry of Health’s orders and a member of the working group of Regulatory Impact Assessment in Ministry of Economic Development

Is a member of the working group on implementation of the "regulatory guillotine" reform in the field of pharmaceuticals and medical devices of the Russian Government

Is a member of the Expert Council on Improving Medical Education and Personnel Policy in Healthcare of the State Duma of the Russian Federation.

 

 

Ilya received his Specialist’s degree in economics and mathematics from Financial University under the Government of the Russian Federation, and then continued his education in Diplomatic Academy of the Russian Ministry of Foreign Affairs receiving his Master’s degree in management. Ilya has more than 10 years’ extensive leadership experience at Bayer. Ilya joined the company as the Head of controlling department, then, for several years, had an international assignment in CH HQ in Switzerland. Currently he is the Head of PMO and BD&L, Cluster Russia, Ukraine and CIS. Ilya’s areas of responsibilities include business analytics and market analysis, also management of divisional strategic projects (including localization) and business development (innovations and e-commerce).

+ 10 years of working experience in public

administration in customer Service, and

at Merck in the supply chain management

of medicinal products

 

Current Position

Since February 2018: Supply Chain Head, Merck Biopharma Russia & CIS

 

Professional background

2015 ~ 18  Demand Planning Manager; Merck Spain

2012 ~ 15  Customer Service Technician, Customer Service Manager; Open    Administration Consortium

2006 ~ 12  Product Manager, Project Manager; Catalan Certification Agency

Tatarnikova Anastasia Aleksandrovna, journalist and manager economist by education, has been involved in public activities in the field of Rare Diseases since 2011.

She is the head of the organization for patient care - ICO "Another Life" and the Chairman of the "Center for expert assistance on issues related to Rare Diseases “Home for Rares”. In addition to providing organizational, legal, informational and other kind of assistance to the patients in the exact nosological areas, ANO “Home for Rares” and its experts are active participants of regional and federal socio-political events aimed at improving the quality and availability of medical care and drug provision for "rare" patients.

Vilena Galkina

Head of Government Relations Department, GEROPHARM

Vilena graduated from the State University of Management with a degree in Public Relations in 2008. In 2018, she completed additional education at the St. Petersburg State Chemical and Pharmaceutical University, Department for Regulation of Circulation of Medicines in Pharmaceutical Market.

 Her professional experience in pharmaceutical business goes back to 2008. She worked in consulting companies cooperating with major international and Russian companies.

 In 2012, she joined GEROPHARM. Vilena is an expert and a regular participant in discussions on topical issues related to industry regulation.

Rustam Iksanov, Vice President, R&D, co-developer of more than 10 inventions in the field of pharmacy, which are protected by patents of the Russian Federation.

 Rustam Iksanov has been working in the Russian pharmaceutical market for more than 20 years. Before joining NovaMedica he took the position of M&A Director in Valenta Pharm where he managed the business development of Gastroenterology division. He developed strategic scenarios of product portfolio development, managed pipeline projects and was responsible for search of potential targets for acquisition (products, developments and companies), preparation and implementation of deals.

Earlier Rustam was Vice President for Strategic Development in Akrikhin (Polpharma), he also hold managerial positions in the field of development products and product portfolio in Izvariono Pharma (Ferring Pharmaceuticals) and Nizhpharm (Stada). Before that, he held classes at the Nizhny Novgorod State Medical Academy and worked as a physician.

Rustam graduated with honors from the Nizhny Novgorod State Medical Academy. In addition, he undertook special programs devoted to commercialization of technologies in the Russian Presidential Academy of National Economy and to pharmaceutical management and economics in the Peoples’ Friendship University of Russia.

Director of the Federal State Unitary Enterprise “The Saint Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial Preparations” of the Federal Medical and Biologic Agency.

Since January 2019, Irina Romanova has headed Sanofi's Consumer Healthcare business in the Eurasia zone. Prior to that, since 2016, Irina was leading CHC business in Russia and Belarus in the role of General Manager. Irina started her career in the pharmaceutical industry over 20 years ago as a medical representative. Through this journey, she held various positions to drive profitable growth and market share gains within International pharma companies, such as Nycomed and Novartis.

Anastasia Altaychinova joined Sanofi's Consumer Healthcare sales team in April 2017, as Head of Excellence. In December 2018, Anastasia was appointed as Customer Development Head to lead a newly created department, and later in July 2019, she was promoted to the position of National Sales Manager. Anastasia received her medical degree at the I.M. Sechenov First Moscow State Medical University, with major in obstetrician-gynecologist. After graduation she worked in sales departments at various leading pharmaceutical companies such as Bayer and MSD, where she was responsible for prescription and OTC drug portfolios.

Kirill has over 10 years of experience in leadership positions at top international pharmaceutical companies such as Abbott, Novartis and Takeda.
In 1998 Kirill graduated from the Faculty for Training of Scientific and Pedagogical Personnel at Sechenov Moscow Medical Academy, and in 1999 degree International Master of Public Health at Hebrew University-Hadassah Braun School of Public Health and Community Medicine (Jerusalem, Israel). In 2003, Kirill defended PhD thesis from the Faculty of Healthcare Management of the Sechenov Moscow Medical Academy. In 2006 he received Doctor of Philosophy degree from the London School of Hygiene and Tropical Medicine, and in 2011 received Doctor of Medical Sciences degree from the Sechenov Moscow Medical Academy
Kirill is a professor of Health Care Administration and Economy program at Higher School of Economics. He has more than 50 scientific publications.

As Director General, Ms Svarcaite is responsible for providing strategic direction and leadership while managing the day to day operations of Association of the European Self-Care Industry (AESGP) and its ongoing relationships with its member associations, companies and other stakeholders, as well as representing the self-care industry in various International, European and national forums. The Association of the European Self-care Industry (AESGP) represents the manufacturers of non-prescription medicines, food supplements and self-care medical devices in Europe, an area also referred to as consumer healthcare products. Her previous work experience includes the Secretary General position at the Pharmaceutical Group of the EU (PGEU), an umbrella organization representing community pharmacy in Europe, the head of Pharmaceutical Care Department in a major pharmacy chain in Lithuania. Ms. Svarcaite received her Master in Pharmacy degree from Kaunas University of Medicine, Kaunas, Lithuania. She went on to earn her Master of Science degree in Pharmacy Practice from The School of Pharmacy, University of London.

Since 2000 in pharmaceutical business. Experience in managing sales and marketing teams. Since 2012 head of the BREFFI company — the leader in omnichannel promotion of pharmaceutical brands. Author of unique products and services for brand promotion: STORY CLM, PSP Nezabudka, BreffiAcademy, BreffiEvent, Ya expert, Ordinatorskaya online.

25+ years of business development experience at various industries in Russia & CIS market - pharmaceutical, manufacturing, oil&gas, software development, IT & system integration.


Recognized for building high-performance teams that ensure on-target completion of complex project deliverables, attain quota assignments and other business related KPIs for such companies as IQVIA, Software AG, Microsoft, Optima.

 

Possess profound expertise in key business development areas:

·         Corporate Sales Development

·         Business Process Management & Improvement

·         Go-to-Market Planning

·         Digital Business Transformation Platforms & Programs 

·         Project Management

·         P&L Tracking and Optimization

·         Change management & Team motivation

 

Master of science in physics, Bachelor of Economics

Valery Eremenko, PhD, has over 20 years’ experience in the area of dispute resolution, specialising in corporate and antitrust disputes, as well as real estate, securities and intellectual property litigation. Valery has unique experience in litigation due to his involvement and oversight of over 1500 litigation proceedings. He has represented his clients before the Presidium of the Supreme Arbitration Court of the Russian Federation in a number of precedent-setting disputes as well as before the Supreme Court of the Russian Federation.

Graduated from the Moscow state Institute of radio engineering, electronics and automation. Since 2001, she began her career in the field of systems and business analysis, since 2006 in the field of pharmaceutical marketing. Has experience in leading Russian and foreign analytical companies in the pharmaceutical sector.

Andrey Zelenin is the Lidings' Managing Partner, advocate, with 15+ years of experience in supporting international business in Russia. Focused on corporate and M&A issues, dispute resolution and intellectual property matters. Ranked by major Russian and international legal ratings as an outstanding litigation and intellectual property lawyer in Russia, recommended as the prominent expert in the sphere of Life Sciences.